Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q2 FY23 Earnings Presentation
41 slides from Camlin Fine Sciences's earnings presentation, Nov 12, 2022
Slide 1: Regulation 30 intimation to stock exchanges
November 12, 2022 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai‐ 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Intimation
Slide 2: Camlin Fine Sciences Ltd. Investor Presentation – November 2022
Camlin Fine Sciences Ltd. Investor Presentation – November 2022
Slide 3: Safe Harbour
Safe Harbour 5 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for a
Slide 4: Q2 & H1 FY23 Highlights
Q2 &H1 FY23 Highlights #start your story
Slide 5: Q2 FY23 Operational Highlights
Q2 FY23 Operational Highlights 5 Revenue Rs. 4, 832 Mn EBITDA Rs. 552 Mn PAT Rs. 99 Mn +353% Growth on YoY basis +55% Growth on YoY basis +99% Growth on YoY basis Operational Updates › Highest ever quarterly & half-yearly operating revenue › Robust growth in the operating revenues of 26% quarter on
Slide 6: Performance Highlights
Performance Highlights 5 Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 8.9% 12.8% 11.4% -1.3% 0.9% 2.0% Margin Quarterly Highlights +55% +99% +353% 4,832 552 99 3,838 492 3,112 277 36 Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 -39 Q2FY22 Q1FY23 Q2FY23 11.4% 12.1% 3.1% 1.6% Half Year Highligh
Slide 7: Operational Revenue Break-up
Operational Revenue Break-up 5 Shelf Life Extension (Rs. In Mn) Blends (Rs. In Mn) Total Shelf Life Solution (Rs. In Mn) +51% +35% +42% 2,362 2,540 4,902 +91% +59% +34% 1,880 3,448 1,450 1,568 1,296 2,746 759 971 1,730 Q2FY22 Q2FY23 H1FY22 H1FY23 Q2FY22 Q2FY23 H1FY22 H1FY23 Q2FY22 Q2FY23 H1FY22 H1FY
Slide 8: Regional Highlights
Regional Highlights 5 CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) +40% +19% +32% 3,986 1,800 2,875 +76% 1,513 +18% +39% 2,177 2,839 2,431 901 1,552 762 1,117 1,382 Q2FY22 Q2FY23 H1FY22 H1FY23 Q2FY22 Q2FY23 H1FY22 H1FY23 Q2FY22 Q2FY23 H1FY22 H1FY23 CFS Brazil (Rs. In Mn) CFS N
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement 5 Particulars (Rs. In Mn) Q2FY23 Q2FY22 YoY H1FY23 H1FY22 YoY Revenue from Operation 4,832.5 3,112.2 55.3% 8,670.2 6,420.5 35.0% Raw material consumption 2,384.6 1,709.1 4,166.0 3,539.1 Employee Cost 389.6 345.5 800.8 673.1 Other expenses 1,506.2 830.5 2,660.8 1,
Slide 10: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement 5 Particulars (Rs. In Mn) Q2FY23 Q2FY22 YoY H1FY23 H1FY22 YoY Revenue from Operation 2,431.5 1,381.7 76.0% 3,985.9 2,838.9 40.4% Raw material consumption 1,185.1 861.3 1,968.1 1,710.2 Employee Cost 129.5 131.0 269.6 244.0 Other expenses 694.8 359.8 1,169.8 654.0 EB
Slide 11: Consolidated Balance Sheet
Consolidated Balance Sheet 5 Particulars (Rs. In Mn) Sep - 22 Mar - 22 Particulars (Rs. In Mn) Sep - 22 Mar - 22 Equity Non-Current assets Equity Share Capital 157.1 157.0 Property, Plant and Equipment 4,656.5 4,818.3 Other Equity 7,346.0 7,322.4 Capital Work-In-Progress 3,298.3 2,147.1 Minority int
Slide 12: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement 5 Particulars (Rs. In mn) Sep - 22 Sep- 21 Net Profit Before Tax 401.6 333.1 Adjustments for: Non Cash Items / Other Investment or Financial Items 607.8 390.1 Operating profit before working capital changes 1,009.4 723.2 Changes in working capital -739.2 83.5 Cash ge
Slide 13: Bringing Science to Everyday Life
B r i n g i n g S c i e n c e t o E ve r y d ay L i fe #start your story
Slide 14: Company Overview
Company Overview 5 Camlin Fine Sciences Ltd. is a vertically integrated company, engaged in the research, development, manufacturing, commercializing, and marketing of specialty chemicals and blends. 2006 Leading Preferred manufacturer of Partner for Established Antioxidants Customised Products Rs 8
Slide 15: Business Verticals & Industries Served
Business Verticals & Industries Served 5 Business Mix H1 FY23* <1% <1% 42% 58% Sales Mix › Functional Foods › Pharma Intermediates › Food End User Industries › Feed & Food › Personal Care & Home Care › Livestock Feed › Petrochemicals › Animal Nutrition › Flavours & Fragrances › Dietary Supplements ›
Slide 16: Strategically Located
Strategically Located 5 80+ Countries USA Italy China Presence Mexico Cuba India Dominican Gautemala Republic Colombia Singapore 1,000+ Customers Peru Brazil Chille Argentina CFS Wanglong CFS North CFS Dresen (Dresen Camlin Fine Sciences & ` CFS do Brasil Ltda. CFS Europe SpA Flavours (Ningbo), Amer
Slide 17: Global Research & Development
Global Research & Development 5 Application Labs › Develops customized blends for various applications › Provides technical assistance and development support to customers • Mexico City › Tests of defined performance parameters • Des Moines, USA › Conducts stability studies for various products of s
Slide 18: Over The Decades, A Prestigious Brand Has Emerged
Over The Decades,A Prestigious Brand Has Emerged 5 FY94 FY07 FY12 FY14 › Camlin Fine Chemical division › Camlin Fine Sciences Ltd. was › Acquired Borregaard Italia › Introduced extensive range of incorporated in Camlin Ltd. to formed after de-merging SpA, a manufacturing facility in performance chem
Slide 19: Complex Chemistry With High Barriers
Complex Chemistry With High Barriers 5 Long Gestation Period High Replacement Cost Tight Regulations Our global presence, growing scale, Complying with a wide range of laws, Customer acquisition takes a long reliable supply chain, rationalized cost regulations and practices, including time, thus the
Slide 20: Key Strengths
Key Strengths 5 1 Leading, global player in shelf-life solutions across food, feed, pet-food and Biodiesel 2 Local presence in major global markets 3 Advanced R&D facilities & Application Labs 4 Proven ability to acquire and improve business performance 5 Vertically integrated across the value chain
Slide 21: Business Overview
Business Overview #start your story
Slide 22: Shelf Life Solutions
Shelf Life Solutions 5 End User Industries Total Operational Revenue (Rs. in Mn) Product portfolio 7,980 Foods 6,171 Antioxidants (straights) Blends & Other Additives 5,516 3,812 4,856 4,902 2,860 Established player in the global market with over 2,381 Pet Food 2,248 2,362 30 years of experience 4,1
Slide 23: Performance Chemicals
Performance Chemicals 5 End User Industries › Performance Chemicals are specialty chemicals sold on the basis of their Total Operational Revenue (Rs. in Mn) performance for specific industrial applications › Entered into a long-term preferred supply agreement with Lockheed Martin Advanced Energy Sto
Slide 24: Aroma Ingredients
Aroma Ingredients 5 End User Industries › CFS produces Vanillin through the Catechol route and its brand is one of the Total Operational Revenue (Rs. in Mn) most trusted by the Food and Flavours Industry. › Vanillin is a synthetic substitute to natural vanilla derived from vanilla beans, which is ve
Slide 25: Health & Wellness
Health & Wellness 5 End User Industries › Launched in 2019 to cater to the rising awareness and growing demand for natural products. › Offers nutraceutical products derived by plant extraction and fermentation such as natural colours, Pet Food functional ingredients, plant-based extracts in natural
Slide 26: CFS 2.0
CFS 2.0 #start your story
Slide 27: CFS 2.0
CFS 2.0 5 CFS CFS 1.0 2.0 Further Improving Advancing Expansion in Preparing Operational Growth Acceleration Downstream For Future Efficiencies Strategies Products 26
Slide 28: Manufactured In-house: Integration Chain
Integration Chain 5 Phenol Manufactured In-house Hydroquinone Diphenols Catechol Performance Performance Shelf Life Solutions Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Catechol Ethyl
Slide 29: Improving Operational Efficiencies
Improving Operational Efficiencies 5 Key Rational Before Dahej Expansion: After Dahej Expansion: › Backward Integrated through Italy & Dahej Facility › Diphenols were manufactured in Italy and › Diphenol captive requirement in India will be met › Became one of the leading low cost transported to man
Slide 30: Well Placed to Expand Downstream Products
Well Placed to Expand Downstream Products 5 Wide Product Basket Key Products Our Presence Hydroquinone Catechol › High Volatile Business › High Volatile Business › Supply Deficit in Global Market › Oversupply in Global Market MEHQ › High Demand › Moderate Demand BHA Guaiacol Ascorbyl Palmitate CFS 2
Slide 31: Advancing Our Growth Strategy
Advancing Our Growth Strategy 5 › With a diverse product portfolio, worldwide presence, › 15,000 MT greenfield facility at Dahej, Gujarat strengthens the CFS continuous focus on R&D, and healthy financial position, capabilities in Diphenols CFS is well-positioned to benefit from sectoral Dahej Facil
Slide 32: Preparing For Future Growth
Preparing For Future Growth 5 Building Additional Multipurpose Plant › Setting up 6,000 MT Vanillin facility at Dahej, Gujarat to make Vanillin, Ethyl Vanillin, Methyl Vanillin, and its derivatives › The low-cost Catechol obtained from the latest Dahej facility will improve EBITDA margins, giving CF
Slide 33: Way Forward: Acceleration
Way Forward : Acceleration 5 Acceleration SHELF-LIFE SOLUTIONS AROMA INGREDIENTS › Increasing focus on high margin blends and › Setting up 6,000 MT Vanillin facility at Dahej additives › Focusing on cost efficient manufacturing of › Introducing new products, cross-selling Vanillin leading to improve
Slide 34: ESG Highlights
ESG Highlights 5 › Carefully chosen product portfolio to provide environmental benefits addressing large societal challenges like food waste prevention. Environment › CFS is proactively working towards sourcing clean energy from wind energy farm with a capacity of 1.25MW which could replace upto 20%
Slide 35: Key Clients and Certificates
Key Clients and Certificates 5 Key Clients Key Certificates The Brand Names and Logos mentioned are the property of their respective owners and are used here for identification purposes only 34
Slide 36: Board of Directors
Board of Directors 5 Ashish Dandekar Nirmal Momaya Arjun Dukane Harsha Raghavan Chairman & Managing Director Managing Director Executive Director - Technical Non Executive Non-Independent • BA in Economics and Management studies form • CA with over 25 years of experience in Finance, Taxation, • Chem
Slide 37: Financial Highlights
Financial Highlights #start your story
Slide 38: Operational Revenue Break-Up
Operational Revenue Break-Up 5 Shelf Life Extension (Rs. In Mn) Blends (Rs. In Mn) Total Shelf Life Solution (Rs. In Mn) 3,812 4,168 7,980 2,860 3,135 3,311 6,171 5,516 2,248 2,381 2,362 2,608 2,540 4,856 4,902 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 FY22 H1FY23 Performa
Slide 39: Regional Highlights
Regional Highlights 5 CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 6,855 3,198 4,395 5,798 6,000 2,735 3,762 5,481 2,571 3,296 3,091 2,172 2,875 3,986 1,800 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 FY22 H1FY23 CFS Brazil (Rs. In Mn) CFS Wanglong (Rs
Slide 40: Historical Financial Highlights
Historical Financial Highlights 5 Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 7.7% 12.5% 15.3% 10.8% 12.1% 0.3% 2.8% 5.5% 4.3% 4.3% Margin 14,121 1,819 654 11,871 604 10,491 1,528 8,922 8,670 1,307 1,047 298 687 135 30 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 FY22 H1FY23 FY19 FY20 FY21 F
Slide 41: Thank You
Thank You Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – [email protected] www.camlinfs.com #start your story Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Jigar Kavaiya Email – [email protected] www.sgapl.net 40